Dino Di Carlo的动态

We continue to feature the most popular and impactful articles published in 2023 in our journal, Antibody Therapeutics (2022 CiteScore: 6.4). The title of the 9th article we’d like to feature is “Alpaca single B cell interrogation and heavy-chain-only antibody discovery on an optofluidic platform”. In vivo VHH discovery approaches have been limited by the lack of methodologies for camelid B cell interrogation. The authors at Twist Bioscience reported a novel application of the Beacon? optofluidic platform to the discovery of heavy-chain-only antibodies by screening alpaca B cells. The first and co-corresponding author is Mariya Shapiro, and the other co-corresponding author is Colby Souders who is currently CSO of BrickBio, Inc. ? Antibody Therapeutics (2022 CiteScore: 6.4) is the official journal of Chinese Antibody Society (CAS), a non-profit, non-government global professional organization with focus upon antibody-based therapeutics.?CAS’s 2024 Annual Conference will take place in Cambridge, MA, USA, on Saturday, May 11, 2024. The theme of this conference is “Beyond Borders: Advancements in Antibody-Based Therapeutics in Uncharted Territories". You are welcome to register for the conference right NOW via the following link. https://lnkd.in/ecmFPA4v ? #biologics #antibody #antibodies #antibodydiscovery #antibodytherapeutics #mab #mabs #annualmeeting #annualconference

We highly recommend this excellent review article regarding allosteric antibodies with the title of “Allosteric antibodies : a novel paradigm in drug discovery” The authors define an allosteric antibody as “an antibody that binds to the target on a site/epitope that does not overlap or sterically overlap with the ligand binding site and which subsequently has an impact on the structural dynamics of the target, ultimately modulating its binding and/or activity”. This review delves into the rapidly growing field of allosteric antibodies, highlighting recent therapeutic advancements and novel druggability avenues. The authors also explore the potential of these antibodies as innovative tools in drug discovery and discuss contemporary strategies for designing novel allosteric antibodies, leveraging stateof-the-art computational approaches. The authors of this paper are : ?Léxane Fournier, Enrico Guarnera, Harald Kolmar, and Stefan Becker. Open access to this article at: https://lnkd.in/g6hyb-NW Chinese Antibody Society is an independent non-profit, non-government global professional organization with focus upon antibody-based therapeutics. Our society’s official journal, Antibody Therapeutics is an international peer-reviewed, open access journal published by Oxford University Press, and is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal by June 30, 2025 to enjoy 50% APC (Article Processing Charge/publication fee) discount. . https://lnkd.in/gsTu_U2 #antibodies #antibody #antibodytherapeutics #antibodydiscovery #antibodydevelopment #mabs #mab #biologics

This new open access review article is entitled “Generation of binder-format-payload conjugate-matrices by antibody chain-exchange” and looks very interesting to us. The following is the abstract of this paper: “The generation of antibody-drug conjugates with optimal functionality depends on many parameters. These include binder epitope, antibody format, linker composition, conjugation site(s), drug-to-antibody ratio, and conjugation method. The production of matrices that cover all possible parameters is a major challenge in identifying optimal antibody-drug conjugates. To address this bottleneck, we adapted our Format Chain Exchange technology (FORCE), originally established for bispecific antibodies, toward the generation of binder-format-payload matrices (pair-FORCE). Antibody derivatives with exchange-enabled Fc-heterodimers are combined with payload-conjugated Fc donors, and subsequent chain-exchange transfers payloads to antibody derivatives in different formats. The resulting binder-format-conjugate matrices can be generated with cytotoxic payloads, dyes, haptens, and large molecules, resulting in versatile tools for ADC screening campaigns. We show the relevance of pair-FORCE for identifying optimal HER2-targeting antibody-drug conjugates. Analysis of this matrix reveals that the notion of format-defines-function applies not only to bispecific antibodies, but also to antibody-drug conjugates.” The corresponding author of this excellent paper is the prestigious Dr. Ulrich Brinkmann at Roche Pharma Research and Early Development (pRED). Open access to this paper at: https://lnkd.in/eE95n464 Chinese Antibody Society and its official journal, Antibody Therapeutics jointly organize 2024 mAbTalk Symposium on December 15 in San Diego with the theme of “AntibodyPlus - Bispecific Antibodies and Antibody-Drug Conjugates”. You are welcome to know more information about this symposium and register for it via the following link. https://lnkd.in/gjCEAVxM #antibodies #antibody #antibodytherapeutics #mabs #mab #biologics #adc #adcs #antibodydrugconjugates #antibodydrugconjugate

Antibody Therapeutics (indexed by ESCI, PubMed & Scopus, 2023 CiteScore: 8.7), the official journal of Chinese Antibody Society published by Oxford University Press would like to share a research article entitled “The process using a synthetic library that generates multiple diverse human single domain antibodies”. The corresponding author is Mark Tornetta from Tavotek Biotherapeutics. Single domain antibodies (sdAbs) possess unique characteristics that make them highly effective for developing complex therapeutics. A fully synthetic phage display library can generate VHOs that bind to disease relevant antigen conformations.?Here, researchers demonstrated how screening can identify distinct VHO activities that have been used to generate differentiated drug molecules in various bispecific and multispecific antibody formats. Click the link for the free access of the full article https://lnkd.in/gtZcnhKm We are also welcoming therapeutic antibody related submission through https://lnkd.in/dMJjtiD #Antibody #Therapeutics

Presumably associated with this year’s Nobel Prize in Chemistry regarding AI & protein/antibody, although this paper was published just in this month in Antibody Therapeutics, it already quickly becomes one of the most read papers. The authors of this new open access article from Just - Evotec Biologics describe a novel, cost-effective and accelerated approach to therapeutic antibody discovery, that couples de novo human antibodies derived in silico with high throughput screening technologies. Just-Evotec Biologics’ platform’s applicability is demonstrated here by the identification of a panel of humanoid antibodies that are effective and with high developability potential. The first and corresponding author is Cristina Moldovan Loomis, Ph.D.. #antibodies #antibody #antibodytherapeutics #mabs #mab #biologics #Artificialintelligence #ai

Heading to Breckenridge for Keystone Symposia’s “Antibodies as Drugs: The Art in Antibody Engineering” conference, May 5-8? Don’t miss your chance to learn about Bonum’s technology to generate conditionally activated protein therapeutics, and our lead asset, cLAG3-IL2. ? Talk: “A novel method for generating regulated cytokine therapeutics: Safety and activity of a conditionally active cLAG3-IL2 in a simple antibody format” Presenter: John Mulligan, Ph.D. Date: May 7 | 8-11 am MT ? Poster #1: “Development of a new class of targeted and conditional cytokine therapeutics using a novel dual-binding antibody-based platform” ? Poster #2: “A novel method for generating regulated cytokine therapeutics: Safety and activity of a conditionally active cLAG3-IL2 in a simple antibody format” For more information, read the full release: https://ow.ly/9xZw50RqT0V #ksantibodyeng24 Keystone Symposia on Molecular & Cellular Biology

Allosteric antibodies is a new class, differing in that they are flexible themselves and also change the antigen upon their binding. There are many potential advantages over classical high-binders with perfect steric complementarity, for lots of reasons, one - adaptability to various contexts and environments of every cell.

??Exciting News in Antibody Discovery! We're thrilled to announce the groundbreaking collaboration between Cyagen and Biointron, bringing a new era of innovation to fully human antibody discovery. The Cyagen HUGO-Ab? & Biointron AbDrop? platform, designed for high-throughput and fully humanized antibody development, sets a new standard in the field. Key Benefits: ? Faster Results: Go from target to fully human antibody in just 3 months. ? Enhanced Accuracy & Diversity: Access a diverse pool of high-quality antibody sequences. ? Cost-Effective: Significant reduction in development costs and timelines. ? Simplified Process: Streamlined IP and patent licensing. Our unique combination of HUGO-Ab? fully humanized mice and AbDrop? microdroplet technology enhances the discovery process, ensuring high-affinity, low-immunogenic antibodies that lead to safer and more effective therapeutics. With proven performance recognized by top pharmaceutical firms and academic institutions, we're paving the way for new antibody-based therapies. Discover more about how this next-generation platform can revolutionize your antibody drug development. Join us in transforming lives with cutting-edge innovation! Learn more here: https://lnkd.in/gVWyhhWc #antibodydiscovery #biotechnology #scienceandtechnology #biotech #biosciences #healthcare #drugdiscovery #preclinicalresearch?

We are pleased to announce a strategic partnership with DPBIO, an industry leader in droplet microfluidics technology, to accelerate innovation in antibody drug development. This collaboration integrates DPBIO’s Cytospark? droplet microfluidic single-B cell antibody discovery platform with Leveragen’s Singularity Sapiens Mouse, a next-generation genetic platform for generating fully human single-domain antibodies. DPBIO’s high-throughput Cytospark? platform drastically reduces screening time while maintaining exceptional precision, enabling the rapid identification of functional antibodies. Leveragen’s Singularity Sapiens Mouse produces fully human single-domain antibodies with unparalleled diversity, affinity, and stability, addressing critical challenges in traditional approaches. Together, this partnership aims to deliver transformative technologies, creating innovative solutions for complex therapeutic targets and advancing the development of next-generation biologics to address unmet medical needs. https://lnkd.in/ewY8YA5P #BostonBiotech #MassBio #AntibodyTherapeutics #AntibodyEngineering #TheAntibodySociety

HuMab’s AiCE Technology: Pioneering a Path to Becoming ‘K-Regeneron’ Regeneron, a globally renowned biotech leader, has built a legacy through its distinctive “new drug-only” business model. At its core lies the VelocImmune platform, a humanized mouse technology instrumental in developing blockbuster drugs. This innovation underscores the potential of fully human antibodies, produced via transgenic mouse platforms, to deliver superior biophysical properties and reduced immune responses. However, the steep barriers to developing such technologies leave South Korean companies questioning whether the dream of a “K-Regeneron” is within reach. To explore this challenge, HitNews engaged in an in-depth discussion with Chang-gyu Oh, CEO of HuMab, a South Korean biotech developing SynThese, a next-generation humanized transgenic mouse platform. Our follow-up conversation delved deeper into the platform’s potential and its implications for the future of antibody therapeutics.